Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Beam Therapeutics (Nasdaq: BEAM), a biotechnology company specializing in precision genetic medicines through base editing, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO John Evans will deliver a presentation on January 13, 2025, at 1:30 p.m. PT in San Francisco. The presentation will be accessible via live webcast on the company's website investor section at www.beamtx.com and will remain available for 60 days after the event.
Beam Therapeutics (Nasdaq: BEAM), un'azienda biotecnologica specializzata in medicina genetica di precisione attraverso l'editing basale, ha annunciato la sua partecipazione al 43° Congresso Annuale della Sanità J.P. Morgan. Il CEO John Evans presenterà il suo intervento il 13 gennaio 2025, alle 13:30 PT a San Francisco. La presentazione sarà accessibile tramite webcast live nella sezione investitori del sito web dell'azienda all'indirizzo www.beamtx.com e rimarrà disponibile per 60 giorni dopo l'evento.
Beam Therapeutics (Nasdaq: BEAM), una compañía de biotecnología especializada en medicinas genéticas de precisión a través de la edición de bases, ha anunciado su participación en la 43ª Conferencia Anual de Salud J.P. Morgan. El CEO John Evans dará una presentación el 13 de enero de 2025, a la 1:30 p.m. PT en San Francisco. La presentación estará disponible a través de streaming en vivo en la sección de inversores del sitio web de la compañía www.beamtx.com y permanecerá accesible durante 60 días después del evento.
Beam Therapeutics (Nasdaq: BEAM), 유전자 편집 기술을 통한 정밀 유전자 치료제를 전문으로 하는 생명공학 회사가 제43회 J.P. Morgan 헬스케어 컨퍼런스에 참여한다고 발표했습니다. CEO인 John Evans는 2025년 1월 13일, 오후 1시 30분 PT에 샌프란시스코에서 발표를 할 예정입니다. 발표는 회사 웹사이트의 투자자 섹션인 www.beamtx.com에서 라이브 웹캐스트로 시청할 수 있으며, 이벤트 후 60일 동안 이용 가능합니다.
Beam Therapeutics (Nasdaq: BEAM), une entreprise de biotechnologie spécialisée dans les médicaments génétiques de précision grâce à l'édition de bases, a annoncé sa participation à la 43ème Conférence Annuelle de Santé J.P. Morgan. Le PDG John Evans fera une présentation le 13 janvier 2025 à 13h30 PT à San Francisco. La présentation sera accessible en diffusion en direct sur la section investisseurs du site internet de la société www.beamtx.com et restera disponible pendant 60 jours après l'événement.
Beam Therapeutics (Nasdaq: BEAM), ein Biotechnologieunternehmen, das sich auf präzise genetische Medikamente durch Basenbearbeitung spezialisiert hat, hat seine Teilnahme an der 43. J.P. Morgan Healthcare Conference bekanntgegeben. CEO John Evans wird am 13. Januar 2025, um 13:30 Uhr PT in San Francisco eine Präsentation halten. Die Präsentation wird über Live-Stream im Investorenbereich der Unternehmenswebsite unter www.beamtx.com verfügbar sein und bleibt 60 Tage nach der Veranstaltung zugänglich.
- None.
- None.
CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 1:30 p.m. PT in San Francisco.
A live webcast will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Contact:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com
FAQ
When is Beam Therapeutics (BEAM) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Beam Therapeutics' (BEAM) J.P. Morgan Healthcare Conference presentation?
Who will represent Beam Therapeutics (BEAM) at the 2025 J.P. Morgan Healthcare Conference?
How long will Beam Therapeutics' (BEAM) J.P. Morgan Conference presentation be available online?
